284 related articles for article (PubMed ID: 21606452)
1. Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease.
Ramlackhansingh AF; Bose SK; Ahmed I; Turkheimer FE; Pavese N; Brooks DJ
Neurology; 2011 May; 76(21):1811-6. PubMed ID: 21606452
[TBL] [Abstract][Full Text] [Related]
2. Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease.
Kase H; Aoyama S; Ichimura M; Ikeda K; Ishii A; Kanda T; Koga K; Koike N; Kurokawa M; Kuwana Y; Mori A; Nakamura J; Nonaka H; Ochi M; Saki M; Shimada J; Shindou T; Shiozaki S; Suzuki F; Takeda M; Yanagawa K; Richardson PJ; Jenner P; Bedard P; Borrelli E; Hauser RA; Chase TN;
Neurology; 2003 Dec; 61(11 Suppl 6):S97-100. PubMed ID: 14663020
[TBL] [Abstract][Full Text] [Related]
3. A2A receptor antagonists do not induce dyskinesias in drug-naive or L-dopa sensitized rats.
Jones N; Bleickardt C; Mullins D; Parker E; Hodgson R
Brain Res Bull; 2013 Sep; 98():163-9. PubMed ID: 23838432
[TBL] [Abstract][Full Text] [Related]
4. Adenosine A
Waggan I; Rissanen E; Tuisku J; Joutsa J; Helin S; Parkkola R; Rinne JO; Airas L
J Neurol; 2023 Jan; 270(1):300-310. PubMed ID: 36053386
[TBL] [Abstract][Full Text] [Related]
5. Occupancy of adenosine A
Ishibashi K; Miura Y; Wagatsuma K; Toyohara J; Ishiwata K; Ishii K
Neuropharmacology; 2018 Dec; 143():106-112. PubMed ID: 30253174
[TBL] [Abstract][Full Text] [Related]
6. Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients.
Politis M; Wu K; Loane C; Brooks DJ; Kiferle L; Turkheimer FE; Bain P; Molloy S; Piccini P
J Clin Invest; 2014 Mar; 124(3):1340-9. PubMed ID: 24531549
[TBL] [Abstract][Full Text] [Related]
7. Adenosine A(2A) receptors measured with [C]TMSX PET in the striata of Parkinson's disease patients.
Mishina M; Ishiwata K; Naganawa M; Kimura Y; Kitamura S; Suzuki M; Hashimoto M; Ishibashi K; Oda K; Sakata M; Hamamoto M; Kobayashi S; Katayama Y; Ishii K
PLoS One; 2011 Feb; 6(2):e17338. PubMed ID: 21386999
[TBL] [Abstract][Full Text] [Related]
8. Role of adenosine A
Pinna A; Serra M; Morelli M; Simola N
J Neural Transm (Vienna); 2018 Aug; 125(8):1273-1286. PubMed ID: 29396609
[TBL] [Abstract][Full Text] [Related]
9. Altered adenosine 2A and dopamine D2 receptor availability in the 6-hydroxydopamine-treated rats with and without levodopa-induced dyskinesia.
Zhou X; Doorduin J; Elsinga PH; Dierckx RAJO; de Vries EFJ; Casteels C
Neuroimage; 2017 Aug; 157():209-218. PubMed ID: 28583881
[TBL] [Abstract][Full Text] [Related]
10. Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications.
Morelli M; Di Paolo T; Wardas J; Calon F; Xiao D; Schwarzschild MA
Prog Neurobiol; 2007 Dec; 83(5):293-309. PubMed ID: 17826884
[TBL] [Abstract][Full Text] [Related]
11. Modulation of GABAergic transmission in the striatopallidal system by adenosine A2A receptors: a potential mechanism for the antiparkinsonian effects of A2A antagonists.
Mori A; Shindou T
Neurology; 2003 Dec; 61(11 Suppl 6):S44-8. PubMed ID: 14663009
[TBL] [Abstract][Full Text] [Related]
12. Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias.
Piccini P; Weeks RA; Brooks DJ
Ann Neurol; 1997 Nov; 42(5):720-6. PubMed ID: 9392571
[TBL] [Abstract][Full Text] [Related]
13. Adenosine receptors and dyskinesia in pathophysiology.
Tomiyama M
Int Rev Neurobiol; 2014; 119():117-26. PubMed ID: 25175963
[TBL] [Abstract][Full Text] [Related]
14. Adenosine A(2A) receptors in nonlocomotor features of Parkinson's disease: introduction.
Ongini E
Neurology; 2003 Dec; 61(11 Suppl 6):S72-3. PubMed ID: 14663015
[No Abstract] [Full Text] [Related]
15. Serotonin-to-dopamine transporter ratios in Parkinson disease: Relevance for dyskinesias.
Roussakis AA; Politis M; Towey D; Piccini P
Neurology; 2016 Mar; 86(12):1152-8. PubMed ID: 26920358
[TBL] [Abstract][Full Text] [Related]
16. Molecular imaging of levodopa-induced dyskinesias.
Niccolini F; Rocchi L; Politis M
Cell Mol Life Sci; 2015 Jun; 72(11):2107-17. PubMed ID: 25681866
[TBL] [Abstract][Full Text] [Related]
17. Brain α7 nicotinic acetylcholine receptors in MPTP-lesioned monkeys and parkinsonian patients.
Morissette M; Morin N; Grégoire L; Rajput A; Rajput AH; Di Paolo T
Biochem Pharmacol; 2016 Jun; 109():62-69. PubMed ID: 27038656
[TBL] [Abstract][Full Text] [Related]
18. Boolean analysis shows a high proportion of dopamine D
Rivas-Santisteban R; Rico AJ; Muñoz A; Rodríguez-Pérez AI; Reyes-Resina I; Navarro G; Labandeira-García JL; Lanciego JL; Franco R
Neurobiol Dis; 2023 Nov; 188():106341. PubMed ID: 37918757
[TBL] [Abstract][Full Text] [Related]
19. Adenosine A2A receptors in neuroadaptation to repeated dopaminergic stimulation: implications for the treatment of dyskinesias in Parkinson's disease.
Chen JF; Fredduzzi S; Bastia E; Yu L; Moratalla R; Ongini E; Schwarzschild MA
Neurology; 2003 Dec; 61(11 Suppl 6):S74-81. PubMed ID: 14663016
[TBL] [Abstract][Full Text] [Related]
20. Effect of dopaminergic medication on adenosine 2A receptor availability in patients with Parkinson's disease.
Waggan I; Rissanen E; Tuisku J; Matilainen M; Helin S; Parkkola R; Rinne JO; Airas L
Parkinsonism Relat Disord; 2021 May; 86():40-44. PubMed ID: 33831661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]